Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront, plus as much as $2.7 billion in milestone payments. The deal with ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other stocks Jim Cramer recently talked about. On Thursday, Jim Cramer, host of Mad Money ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...

Brazil’s strong agricultural sector in sugarcane production significantly contributes to the sodium bisulfite market. BASF, ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Awardees will receive a $1,500 stipend to cover ACS Fall Meeting expenses. They will present their research at a Women Chemists Committee (WCC)/Merck half-day symposium and be recognized at the Awards ...

Sally Beauty Holdings (SBH) saw a slight uptick in shares after reporting mixed Q3 earnings, with revenue up 1.5% and EPS beating consensus.

Its mRNA-4157, in combination with Merck’s Keytruda, demonstrated promising results in early-stage trials for melanoma and ...